<DOC>
	<DOCNO>NCT02098720</DOCNO>
	<brief_summary>This study design evaluate effect Conbercept therapy visual acuity anatomic outcome safety observe subject low vision secondary wet age-related macular degeneration .</brief_summary>
	<brief_title>An Open , Single-center , Safety Efficacy Study Conbercept Patients With Very Low Vision Secondary Wet Age-related Macular Degeneration ( wAMD )</brief_title>
	<detailed_description />
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Vision , Low</mesh_term>
	<criteria>1 . Patients give fully inform consent willing able comply study procedure . 2 . In study eye : There primary recurrent subfoveal parafoveal active choroidal neovascularization ( CNV ) lesion secondary wAMD . The criterion active CNV meet least one follow three condition : fresh bleeding ; neurosensory detachment show optical coherence tomography ( OCT ) ; leakage show fundus fluorescein angiography ( FFA ) . 3 . BCVA study eye &lt; 19 letter ( approximately 20/400 Snellen equivalent ) . 1 . Past exist nonexudative AMD study eye decide investigator affect macular detection central vision ; 2 . Subretinal hemorrhage study eye bleed area ≥6 disc area ; 3 . History vitreous hemorrhage within last month ; 4 . The maximum diameter scar fibrosis area ≥500μm subfoveal study eye ; 5 . Photodynamic therapy ( PDT ) drug treatment CNV within last 6 month study eye , antivascular endothelial growth factor ( VEGF ) therapy fellow eye within last month ; 6 . History glaucoma study eye ; 7 . Aphakia ( exclude artificial lens ) study eye .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>